Regulus Therapeutics Key Fundamental Indicators

RGLSDelisted Stock

USD 8.16 0.01 0.12%

As of the 13th of February 2026, Regulus Therapeutics holds the Risk Adjusted Performance of 0.1776, coefficient of variation of 483.31, and Semi Deviation of 1.47. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regulus Therapeutics, as well as the relationship between them. Please check Regulus Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regulus Therapeutics is priced some-what accurately, providing market reflects its current price of 8.16 per share. Given that Regulus Therapeutics has jensen alpha of 3.71, we recommend you to check out Regulus Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

Regulus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Regulus Therapeutics' valuation are provided below:

Regulus Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

No data is currently available for this entity. Please try again at a later time.

Search Suggestions

R	Ryder System	Company
RF-PC	Regions Financial	Company
RCS	Pimco Strategic Income	Fund
RB	ProShares Trust	ETF
RCI	Dow Jones Composite	Index
RSR	RSR	Cryptocurrency
R9900CAT3	YARNO 7378 14 NOV 32	Corporate Bond
RBUSD	Gasoline RBOB	Commodity

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Based on the latest financial disclosure, Regulus Therapeutics has a Return On Equity of -0.5382. This is 97.75% lower than that of the Biotechnology sector and 98.52% lower than that of the Health Care industry. The return on equity for all United States stocks is 73.61% higher than that of the company.

Regulus Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Regulus Therapeutics's current stock value. Our valuation model uses many indicators to compare Regulus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regulus Therapeutics competition to find correlations between indicators driving Regulus Therapeutics's intrinsic value. More Info.

Regulus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Regulus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Regulus Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.

Regulus Therapeutics is currently under evaluation in return on equity category among its peers.

Regulus Fundamentals

	Return On Equity	-0.54
	Return On Asset	-0.34
	Current Valuation	500.99 M
	Shares Outstanding	69.23 M
	Shares Owned By Insiders	2.70 %
	Shares Owned By Institutions	82.87 %
	Number Of Shares Shorted	2.09 M
	Price To Earning	(0.69) X
	Price To Book	8.19 X
	Price To Sales	7.43 X
	Gross Profit	(36.15 M)
	EBITDA	(45.85 M)
	Net Income	(46.36 M)
	Cash And Equivalents	47.53 M
	Cash Per Share	3.25 X
	Total Debt	274 K
	Debt To Equity	0.17 %
	Current Ratio	8.82 X
	Book Value Per Share	1.04 X
	Cash Flow From Operations	(41.67 M)
	Short Ratio	1.57 X
	Earnings Per Share	(0.68) X
	Price To Earnings To Growth	(0.04) X
	Target Price	7.0
	Number Of Employees	34
	Beta	0.37
	Market Capitalization	564.95 M
	Total Asset	84.18 M
	Retained Earnings	(559.57 M)
	Working Capital	74.85 M
	Current Asset	134.26 M
	Current Liabilities	12.63 M
	Net Asset	84.18 M

About Regulus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Regulus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Consideration for investing in Regulus Stock

If you are still planning to invest in Regulus Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regulus Therapeutics' history and understand the potential risks before investing.

	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC